Buloxibutid

Buloxibutid
	File:Buloxibutid.svg
Clinical data
Other names	VP-01
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate;
CAS Number	477775-14-7;
PubChem CID	9804984;
DrugBank	DB18038;
ChemSpider	7980744;
UNII	RC2V4W0EYC;
KEGG	D13133;
ChEMBL	ChEMBL189568;
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).;
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H29N3O4S2
Molar mass	475.62 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCOC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C=CN=C3;
	InChI InChI=1S/C23H29N3O4S2/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27); Key:XTEOJPUYZWEXFI-UHFFFAOYSA-N;

Buloxibutid is an investigational new drug that is being evaluated to treat COVID-19 infections.^[1] It is an angiotensin II receptor type 2 agonist.^[2] The drug was discovered and developed by Professor Anders Hallberg and colleagues at the University of Uppsala. As at late 2024 it was on large scale trials for treatment of lung fibrosis following successful small-scale trials. Development is supported by investment from Sanofi.^[3]

References

^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ Basic research led to drug candidates for fatal lung disease by Åsa Malmberg, Uppsala University news, 18 November 2024 https://www.uu.se/en/news/2024/2024-11-18-basic-research-led-to-drug-candidates-for-fatal-lung-disease

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.